Thumbay Group wins 4 honors at Sheikh Khalifa Excellence Awards 2018

coastaldigest.com news network
February 21, 2018

Abu Dhabi, Feb 21: UAE-based diversified global conglomerate Thumbay Group has become the first business group in the history of the prestigious Sheikh Khalifa Excellence Awards (SKEA) to win four awards in a single assessment cycle.

At the 16th Sheikh Khalifah Excellence Awards (SKEA) ceremony held under the patronage of Sheikh Mohammad Bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, at the at the Emirates Palace in Abu Dhabi on February 21, 2018, the awards were presented by Sheikh Hamed bin Zayed Al Nahyan, Chairman of Abu Dhabi Crown Prince’s Court, to Dr. Thumbay Moideen, the Founder President of Thumbay Group.

The awards were won by the following entities owned by Thumbay Group:

• Gulf Medical University, Ajman – Gold Award
• Thumbay Hospital, Dubai – Silver Award
• Thumbay Hospital, Ajman – Silver Award
• Thumbay Hospital, Fujairah – Silver Award

Dr Thumbay Moideen said that Thumbay Group was proud to be honored at SKEA. “It is a matter of great pride that we have been honored at the prestigious SKEA awards, not once, but with four awards won by our entities in education and healthcare. I thank the SKEA jury for recognizing our efforts and our commitment to quality. I congratulate my team and I also take this opportunity to thank our customers for the trust they’ve invested in us, during the course of our two decade long journey. We have always striven to set new standards in education and healthcare, two of our core sectors, and ingrained innovation as the underlying function of our operations across all 20 sectors of business that we are involved in.”

Mr. Akbar Moideen Thumbay, the Vice President of Thumbay Group’s Healthcare Division said that the multiple recognitions for the healthcare division recognized not only the high quality of care that is received by patients at Thumbay Hospitals, but “It also emphasizes the fact that our high standards of patient care and service delivery pervade all the departments in all our hospitals.”  He further said, “We take tremendous pride in the fact that people from over 175 countries place their trust in our hospitals in the UAE and Hyderabad-India.”

The SKEA awards are given to both government and private companies and organizations that set and follow best all round business practices in various fields, every year.

About Thumbay Group

Founded by Dr. ThumbayMoideen in 1998, Thumbay Group is a diversified international business conglomerate with operations across 20 different verticals including Education, Healthcare, Medical Research, Diagnostics, Retail Pharmacy, Health Communications, Retail Opticals, Wellness, Nutrition Stores, Hospitality, Real Estate, Publishing, Technology, Media, Events, Medical Tourism, Trading and Marketing & Distribution. Headquartered in Dubai, the group presently employs around 5000 people, which is projected to increase to around 25,000 by the year 2022, with the completion of ongoing and upcoming projects. Currently, Thumbay Group is focusing on its strategic long-term plans which will see the group scale its businesses almost ten times and expand its operations globally.

The Gulf Medical University (GMU), Ajmanis a leading private medical university of the Middle East region, attracting students from over 80 nationalities and employing staff from 25 different countries. The Thumbay network of academic hospitals is now the largest network of private academic hospitals in the Middle East, treating patients from around 175 nationalities. The hospitals, presently located at Dubai, Ajman, Sharjah and Fujairah in the UAE and in Hyderabad – India, are also among the biggest JCI-accredited private academic hospital networks in the region. Thumbay Group’s healthcare division also operates a chain of family clinics (Thumbay Clinic) and multispecialty day care hospitals (Thumbay Hospital Day Care) in the UAE as well as diagnostic labs (Thumbay Labs) and pharmacies (Thumbay Pharmacy) in the UAE and India.

Comments

Muhammed Ali U…
 - 
Thursday, 22 Feb 2018

Masha Allah, great achievement Moideen Saab. To win prestigious Sheikh Khalifa Excellence   awards in a single assessment cycle is highly praiseworthy. Keep the spirit and keep setting and achieving new goals.

Ahmed
 - 
Thursday, 22 Feb 2018

Ma Shaa Allah Mabrook 

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 28,2020

Bengaluru, Mar 28: Sun Tsu, in 'The Art of War' speaks of a skilful general who can subdue his enemy without any fighting. This constitutes the ultimate triumph which is referred to as stratagem. Today, we would need one such when we are faced with the '21-day corona challenge' for India.
Nearly four weeks back, Dr Jyothsna Rao, Dr Gururaj Rao and I sat across the OPD in the afternoon at HCG Bengaluru discussing our ongoing cancer immunology research. While on this topic, we drifted into the discussion on the coronavirus. During this engaging discussion, we wondered the similarity of the enigma between the virus and cancer. I paused to ask Dr Jyothsna and Dr Guru - how we wish we could do something against this virus.
Dr Jyothsna is a PhD from NCBS and had worked under Dr Ralph Steinman, physician and researcher from Rockefeller University, who won the Nobel Prize for his discovery of the dendritic cell and its role in adaptive immunity in 2011. Dr Gururaj is a molecular and cell biologist who did his PhD at the Chapel Hill, University of North Carolina and is the Director of iCrest.
Jyothsna while hearing our perplexing conversation on the covid intervened, "Yes, surely. I think we should take a break from cancer and focus on the innate and adaptive immunity role in COVID-19."
Thus began this sincere attempt to relook the human immune system from the eyes of the COVID-19.
We have 10 types of immune cells at the least which are widely dispersed in millions across the body. When our body is invaded by a foreign organism (bacteria, fungi or virus), these cells work with each other to destroy the invader.
Now, the question is - how do the immune cells talk to each other? They use small-molecule substances called cytokines (cyto means cells; kine means movement). There are many cytokines that are involved in work on the immune system. The most relevant for viruses are interferons.
Interferons (IFN) as the name reflects have an ability to interfere with the viral activity and stop their multiplication. These specialised signal proteins are released by our cells in response to a viral attack to forewarn other cells. They help build the antiviral proteins within the cells to kill the virus as it tries to invade the new cells.
Historically, interferons are a group of cytokines known to be potent antiviral agents against viruses and a hallmark cytokine induced by the host upon viral infections. Interferons possess unique immunoregulatory activities and are signature cytokines released by (TH1) T immune cells, which are crucial in viral infections.
As the outbreak of COVID-19 grapples us, an urgent need for finding strategies to combat the virus is growing. Coronaviruses (CoVs) are a group of RNA viruses. In patients infected with coronavirus, it was indicated that the activation of the IFN does not occur until 48 hours post-infection. Thus the delayed IFN-related antiviral response by the healthy cells leads to coronavirus evade the immune response.
Numerous studies have presented the success in defeating CoVs by the direct administration of IFNs. In a combination as a concoction, it was shown to synergistically inhibit the virus replication in vitro.
Moreover, it is understood that the earlier induction of IFNs in children although they have a less developed immune system could be the reason behind the children being least affected.
The key to success in reducing the disease fatality might be the stimulation of the immune responses to trigger IFN production at the very early stages of the disease, which might be done through the administration of IFN. Despite the evidence for the efficacy of IFNs in treating CoV-induced infections, the proper dosing and ideal timing for such interventions needs to be verified in clinical trials.
For the later stages of the diseases in advance stages where patients are on ventilator and have developed respiratory distress, we propose to utilise the mesenchymal cells derived from donor bone marrow that have been known to treat acute respiratory syndrome. Mesenchymal cells are known to possess anti-inflammatory activity and thus used often in autoimmune diseases.
With this scientific background, we have activated T cells from healthy donors, in a cGMP facility at iCrest - HCG hospital with an enriched cocktail of cytokines rich in Interferons. Injections of this cocktail we believe will result in a surge of cytokines in the body of the infected person and will boost his ability to fight the virus in the early phases. We are in the initial phases of this study and hope to be ready in the coming weeks with meaningful data on its potential utility.
Currently, it awaits government approvals (Union and state) and we have applied to central drugs authority for their initial evaluation and further directions.
As my Guru often expounded the philosophy of 'Seva' - the goal of education is knowledge, the end goal of knowledge is service. In this attempt to serve our fellow humans at this brink of unprecedented crisis, medical fraternity stands with you and promises to do our best for your safety.
We assure to exhaust every bit of our spirit in this fight against coronavirus. We have lost the sight of shores and travelled thus far, but that is the mandatory first step to cross the ocean. Are we going to succeed in this battle, is something only time will answer. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
February 23,2020

Chmarajanagara, Feb 23: In order to control and keep a tab on the activities within the forest area and after the bitter experiences with frequent forest fires, like the one in Bandipur Tiger Reserve last year Karnataka Forest Department officials have decided to use drones to prevent the occurrences of such wildfires, and to use drones to nab trouble makers and take timely action to put out or prevent forest fires, especially during the summer season.

The department of forest has been working on using drones and setting up a centre in Mysuru or Chamarajanagar to monitor three crucial tiger reserves — Bandipur, Nagarhole, and BRT.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 29,2020

Bengaluru, Apr 29: As many as 11 more people have tested positive for the coronavirus in the last 24 hours in Karnataka, said the State's Health Department on Wednesday.

According to an official statement, 11 new COVID-19 positive cases were reported from 5 pm on April 28 to 5 pm on April 29.

"With this, the total number of positive coronavirus cases in the state has mounted to 534, of which 20 deaths have been reported and 215 people have recovered," added the statement.

Of 20 coronavirus patients who died, one death was due to the non-COVID cause, the statement further said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.